• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Mutating Haematopoietic Stem Cells May Cure Sickle Cell Disease

November 16, 2016

Stem Cell Research

Sickle cell disease and β-thalassaemia are caused by mutations in the β -globin gene. Previous studies have shown that transplants of normal β-globin genes into haematopoietic stem cells (HSC) may cure the disease; however, this process is considered inefficient.  New advances recently published in Nature point towards an approach that may improve the efficiency of this intervention.  Researchers were able to correct human HSCs that carry the mutation responsible for sickle cell disease in mice.  Briefly, normal β-globin genes were delivered with an adeno-associated viral vector delivery system into purified human HSCs with the sickle cell gene, and the CRISPR/Cas-9 gene editing system was used to prompt homologous recombination of the normal gene into the target HSCs. New purifying techniques using fluorescence-activated cell sorting or magnetic bead enrichment allowed researchers to collect populations of cells with more than 85% of the normal β-globin gene integrations. These new advances in methodology may help lead to cures for hematological diseases.

Reference:

Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, Porteus MH. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature 2016.

Filed Under

  • Cell Therapy
  • News

Recommended

  • Daprodustat is Noninferior to Erythropoiesis-Stimulating Agents for Patients with Chronic Kidney Disease Undergoing Dialysis

  • FDA Guidance to Control for Bacterial Contamination in Platelets

  • mRNA-1273 Vaccine Safe and Induces anti-SARS-CoV-2 Immune Responses

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley